Should You Buy Tesaro After Its Earnings Miss?
Tesaro just missed earnings estimates by $0.37 per share for its first quarter. Is this stock a bad news buy?
Is Biotech in a Bubble? The Bear Case Explained
Biotech IPOs provide some powerful indications...
Why 2014 May Be a Big Year for Opko Health, Inc.
Opko's (OPK) has a number of catalysts this year that could have a big impact on its biggest investor, Philip Frost; including a Tesaro's (TSRO) potential FDA filing for Rolapitant.
3 Stocks to Get on Your Watchlist
SodaStream, Cisco, and Opko Health are this week's must-watch stocks.
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Five Prime, Bristol-Myers Squibb cut $350M immuno-oncology deal.